Relation Therapeutics vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Relation Therapeutics uses its Lab-in-the-Loop AI platform to discover novel drug targets; secured a $1.7B multi-program Novartis collaboration and a $200M+ GSK partnership; raised $26M additional funding from NVIDIA Ventures in December 2025.
About
Relation Therapeutics is a UK-based clinical-stage biotechnology company that integrates artificial intelligence with experimental biology to discover novel therapeutic targets for diseases with significant unmet medical need. Its proprietary Lab-in-the-Loop platform combines machine learning with patient-derived single-cell multi-omics data, functional assays, and human genetics to identify causal genes and validate novel drug targets — moving beyond correlative genomics to experimental confirmation. The company''s initial therapeutic focus is osteoporosis, with additional programs in immunology, metabolic disease, and fibrosis.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Relation Therapeutics vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.